The PI has been dedicated exclusively to the speciality of Medical Oncology for more than 30 years, developing healthcare, research, and teaching activities that are difficult to separate. The scientific response of the PI in clinical and translational research has allowed the development of numerous clinical trials with cytotoxic drugs and with new drugs directed against speciﬁc molecular targets (onco-pharmacogenomics) and also aimed at individualising treatment (onco-pharmacogenetics) to identify patients most likely to respond. In recent years, he has developed a Translational Research Unit at the Hospital Clínico San Carlos to bring basic aspects as quickly as possible to the clinic (“bench to bedside”). To this end, several projects have been launched with predictive and prognostic factor analysis. The Translational Research Unit of the Hospital Clínico San Carlos de Madrid has shown its potential over the last few years through the development of clinical and laboratory research units and is committed to the development of all the aforementioned lines of research. Identifying predictors of response to new drugs directed against molecular targets is an urgent necessity for a more effective and efficient medicine. These drugs are ineffective in a proportion of the patients to whom they are administered, and their optimisation is absolutely necessary. The group is made up of medical professionals dedicated to clinical care and research, with an important support group of data managers and research nurses, as well as a research laboratory infrastructure equipped with highly qualified and excellent staff and resources.
The following institutions will be eligible for ﬁnancing through the ISCIII: